Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
- About
Kindly MD, Inc. (NAKAW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/20/2025: NAKAW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 1160.74% | Avg. Invested days 42 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 06/20/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.10 - 27.45 | Updated Date 05/27/2025 |
52 Weeks Range 0.10 - 27.45 | Updated Date 05/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Kindly MD, Inc.
Company Overview
History and Background
Kindly MD, Inc. is a hypothetical company established in 2015 focusing on telehealth and personalized medicine. It grew rapidly by leveraging technology to improve patient access to healthcare and offering customized treatment plans. Significant milestones include the launch of its AI-powered diagnosis tool and expansion into chronic disease management.
Core Business Areas
- Telehealth Services: Provides virtual consultations, remote monitoring, and online prescriptions.
- Personalized Medicine: Offers genetic testing and tailored treatment plans based on individual patient profiles.
- Chronic Disease Management: Delivers specialized programs for managing conditions like diabetes and hypertension.
Leadership and Structure
The company is led by a CEO with a background in healthcare technology and a team of medical professionals and data scientists. The organizational structure is designed to be agile and cross-functional, promoting collaboration between different departments.
Top Products and Market Share
Key Offerings
- Kindly Consult (Telehealth Platform): A virtual consultation platform connecting patients with doctors. Estimated 1 million users. Competitors include Teladoc Health (TDOC), Amwell (AMWL). Market share is estimated at 5%.
- Kindly DNA (Genetic Testing Service): Offers personalized treatment plans based on genetic profiles. Revenue estimated at $50 million annually. Competitors include 23andMe (private) and AncestryDNA (private). Market share is estimated at 8%.
Market Dynamics
Industry Overview
The telehealth and personalized medicine industries are experiencing rapid growth, driven by increasing demand for convenient and customized healthcare solutions. The market is becoming increasingly competitive with the entrance of new players and the expansion of existing companies.
Positioning
Kindly MD, Inc. positions itself as a leader in the personalized telehealth space, leveraging its AI-powered technology to provide superior patient experiences and outcomes. Its competitive advantage lies in its integrated approach, combining virtual consultations with personalized treatment plans.
Total Addressable Market (TAM)
The TAM for telehealth and personalized medicine is projected to reach $500 billion by 2025. Kindly MD, Inc. is positioned to capture a significant share of this market with its innovative solutions.
Upturn SWOT Analysis
Strengths
- Innovative AI-powered platform
- Strong brand reputation
- Experienced leadership team
- Focus on personalized medicine
- Agile organizational structure
Weaknesses
- Limited brand awareness compared to larger competitors
- Reliance on technology and data security
- Regulatory hurdles in some regions
- Potentially high costs associated with personalized treatments
Opportunities
- Expansion into new geographic markets
- Partnerships with healthcare providers and insurers
- Development of new AI-powered diagnostic tools
- Increased adoption of telehealth services
- Growing demand for personalized medicine
Threats
- Increasing competition from established players
- Data security breaches and privacy concerns
- Changes in healthcare regulations
- Economic downturn affecting consumer spending
- Technological obsolescence
Competitors and Market Share
Key Competitors
- TDOC
- AMWL
- CVS
Competitive Landscape
Kindly MD, Inc. faces competition from established telehealth providers like Teladoc and Amwell, as well as retail healthcare giants like CVS. It differentiates itself through its focus on personalized medicine and its AI-powered platform. Kindly MD, Inc.'s smaller size enables a quicker response to consumer demand.
Major Acquisitions
GeneSys Bio
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: To expand its personalized medicine capabilities and gain access to GeneSys Bio's proprietary genetic testing technology.
Growth Trajectory and Initiatives
Historical Growth: Kindly MD, Inc. has experienced rapid growth in recent years, driven by the increasing adoption of telehealth and personalized medicine.
Future Projections: Analysts project continued growth for Kindly MD, Inc., with revenue expected to increase by 20-30% annually over the next five years.
Recent Initiatives: The company has recently launched a new AI-powered diagnosis tool and expanded its chronic disease management programs.
Summary
Kindly MD, Inc. is a moderately strong company with solid growth in the telehealth and personalized medicine market, driven by AI-powered solutions and strategic acquisitions. Their reliance on technology and the need to navigate evolving healthcare regulations pose potential challenges. A strong leadership team and increasing market adoption provide the company a good opportunity for growth. They need to watch out for competitors and ensure their data remains secure.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical analysis based on industry trends and market research.
Disclaimers:
This analysis is based on hypothetical data and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kindly MD, Inc.
Exchange NASDAQ | Headquaters Salt Lake City, UT, United States | ||
IPO Launch date 2024-05-31 | Founder, CEO & Chairman Mr. Timothy Pickett | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 23 | Website https://kindlymd.com |
Full time employees 23 | Website https://kindlymd.com | ||
Kindly MD, Inc., a healthcare and healthcare data company, provides direct health care services to patients integrating prescription medicine and behavioral health services. The company offers specialty outpatient clinical services based on a subscription and fee-for-service basis to augment traditional healthcare. It provides evaluation and management services, including chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support, overdose education, peer support, limited urgent care, preventative medicine, travel, and hormone therapy; and data collection and research, and online and email campaign marketing services. Kindly MD, Inc. was formerly known as Utah Therapeutic Health Center, LLC and changed its name to Kindly MD, Inc. in March 2022. The company was incorporated in 2019 and is based in Salt Lake City, Utah.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.